E
Evangelos Terpos
Researcher at National and Kapodistrian University of Athens
Publications - 858
Citations - 33515
Evangelos Terpos is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 73, co-authored 725 publications receiving 25857 citations. Previous affiliations of Evangelos Terpos include Hammersmith Hospital & Imperial College London.
Papers
More filters
Transfusion and Apheresis Science
TL;DR: This review presents all these strategies that aim to cure MM, including continuous treatment i.e. induction, consolidation and maintenance, treatment of asymptomatic MM and monitoring minimal residual disease using modern techniques, such as multi-parameter flow cytometry, molecular assays and advanced imaging.
Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage
Ashraf Z. Badros,Olga Goloubeva,Evangelos Terpos,Todd Milliron,Maria R. Baer,Elizabeth A. Streeten +5 more
TL;DR: The American Society of Clinical Oncology 2007 Clinical Practice Guideline update on the role of bisphosphonates in multiplemyeloma is presented, as well as a review of existing literature on Vitamin D deficiency.
Dignity therapy for patients who are terminally ill
TL;DR: All patients with newly diagnosed, symptomatic multiple myeloma should be treated with zoledronic acid, based on the results of the MRC Myeloma IX study.
Journal ArticleDOI
B03: skeletal-related events and abnormal mri pattern at diagnosis are associated with inferior overall survival in patients with newly diagnosed multiple myeloma
Evangelos Terpos,Nikolaos Kanellias,Ioannis Ntanasis-Stathopoulos,Maria Gavriatopoulou,Efstathios Kastritis,Vassilis Koutoulidis,Despina Fotiou,Magdalini Migkou,Evangelos Eleutherakis-Papaiakovou,Panagiotis Malandrakis,Tina Bagratuni,Maria Roussou,Lia A. Moulopoulos,Meletios A. Dimopoulos +13 more
TL;DR: In this article , a single-center, prospective, observational study was conducted to determine the incidence of SREs among MM patients who received treatment with novel agents during first-line therapy (NDMM) and explore possible correlations with disease characteristics, imaging finding and patient prognosis.